NEW YORK, August 10, 2018 – Levi & Korsinsky is investigating Ampio Pharmaceuticals, Inc. (“Ampio” or “the Company”) (NYSE American: AMPE) concerning possible violations of federal securities laws. On August 7, 2018, Ampio filed a Form 8-K with the U.S. Securities and Exchange Commission providing an update on the U.S. Food and Drug Administration’s review of the AP-003-A and AP-003-C trials. Ampio disclosed that it had met with the FDA in July and received a response letter, notifying the Company that the AP-003-A study alone “does not appear to provide sufficient evidence of effectiveness to support” its Biologics License Application. Following this news, shares of Ampio were down  more than 78% on intraday trading on August 8, 2018. To obtain additional information about the AMPE investigation, go to:http://www.zlk.com/pslra-d/ampio-pharmaceuticals-inc or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.